Pharmaceutical giant Eli Lilly & Co. announced this week that its experimental, next-generation weight-loss therapy demonstrated no overall increase in cardiovascular risk in a major clinical evaluation, successfully clearing a…
The State of Policyholder LoyaltyIn a revealing analysis of fiscal year 2026 data, Mint's examination of NL-47 disclosures has unveiled that the average retention rate for top-selling retail health insurance…